Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Director | January 06, 2021 | January 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date January 06, 2021 · Filed January 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,774 |
Reported balance
After 2021-01-06 transaction · row 1
1 source rowRow 1 · 2021-01-06 · Grant · Acquired 5,921 · Balance 48,774 F1: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2031-01-06 | Direct | 6,850 |
Reported balance
After 2021-01-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-01-06 · Grant · Acquired 6,850 · Balance 6,850 F4: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.11 · Expires 2025-05-07 | Direct | 6,332 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 6,332 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2026-08-24 | Direct | 3,765 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 3,765 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-12-20 | Direct | 4,476 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,476 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.85 · Expires 2028-12-19 | Direct | 5,162 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 5,162 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.57 · Expires 2029-12-16 | Direct | 5,568 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 5,568 F3: This option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 5,194 |
Reported balance
Holding disclosure · report date 2021-01-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,194 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date.
F2: Fully exercisable.
F3: This option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21.
F4: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2021 Filed Jan 8, 2021 17:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 6,850 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0000914190-21-000008 · edgar.xml · derivative · entry 8 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2031-01-06 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 17:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 5,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000008 · edgar.xml · nonDerivative · entry 1 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,774 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| May 11, 2020 Filed May 13, 2020 16:56 UTC | NEPHROS INC NEPH · Entity 7279 | OtherWarrants (right to buy) · Derivative | 1,732 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0000914190-20-000169 · edgar.xml · derivative · entry 3 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 1,732 shares Expires 2020-05-18 Read SEC document |
| May 11, 2020 Filed May 13, 2020 16:56 UTC | NEPHROS INC NEPH · Entity 7279 | OtherCommon Stock | 1,732 | $7.65 | $13,249.80 |
DisclosureSEC source: 0000914190-20-000169 · edgar.xml · nonDerivative · entry 2 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,194 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 17:12 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 5,568 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000914190-19-000505 · edgar.xml · derivative · entry 8 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 Underlying: Common Stock · 5,568 shares Expires 2029-12-16 F5 · derivative.exercise_date: On December 16, 2019, the Company granted an option to purchase 5,568 shares of common stock of the Company (the "Option") in respect of the service by Mr. Persen as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 17:12 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 5,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000505 · edgar.xml · nonDerivative · entry 1 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,853 F1 · shares: On December 16, 2019, the Company granted 5,437 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Persen in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 16:54 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 46,457 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000914190-18-000584 · edgar.xml · derivative · entry 7 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,457 Underlying: Common Stock · 46,457 shares Expires 2028-12-19 F4 · derivative.exercise_date: On December 19, 2018, the Company granted an option to purchase 46,457 shares of common stock of the Company (the "Option") in respect of the service by Mr. Persen as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 15,486 shares on each of 12/19/18 and 12/19/19, and as to 15,485 shares on 12/19/20. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 17:28 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 71,509 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000569 · edgar.xml · nonDerivative · entry 1 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,750 F1 · shares: On December 14, 2018, the Company granted 71,509 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Persen in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 11:34 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 40,284 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000914190-17-000393 · edgar.xml · derivative · entry 6 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,284 Underlying: Common Stock · 40,284 shares Expires 2027-12-20 F4 · derivative.exercise_date: On December 20, 2017, the Company granted an option to purchase 40,284 shares of common stock of the Company (the "Option") in respect of the service by Mr. Persen as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 11:34 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 113,636 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000393 · edgar.xml · nonDerivative · entry 1 PERSEN MALCOLM C · CIK 0001287975 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,241 F1 · shares: On December 20, 2017, the Company granted 113,636 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Persen in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.